---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-22-000141"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:10:53.403205+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions Q3 revenues down 27% to $240M; net loss widens to $75.7M; guidance slashed

## Summary
- Total revenues $240M (-27% YoY); net loss $75.7M (-$1.52 EPS) vs loss $32.7M (-$0.61) prior year.
- Segment: Products revenue $186.2M (-31%); Services CDMO $36.4M (-13%); nasal naloxone -34%, ACAM2000 -39%, anthrax vaccines +55%.
- Completed TEMBEXA acquisition from Chimerix; BARDA contract up to $680M for 1.7M doses over 10 years.
- FY2022 guidance revised down: total rev $1.05-1.1B (from $1.15-1.25B); adj EBITDA $0-30M (from $80-120M); ACAM2000 cut to $63M.
- Gross margin improved to 33% from 30%; adjusted gross margin 34% from 31%; attributed to mix shift.

## SEC filing metadata
- accession: 0001367644-22-000141
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000141/0001367644-22-000141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000141/ebs-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-22-000141
- JSON: https://secwatch.observer/filing/0001367644-22-000141.json
- Plain text: https://secwatch.observer/filing/0001367644-22-000141.txt

## Key facts
- Earnings Releases
  Emergent BioSolutions Inc. reported the third quarter ended September 30, 2022 results: revenue Total Revenues $240.0, net income Net Loss $(75.7), EPS Net Loss per Diluted Share $(1.52).
  - Period: the third quarter ended September 30, 2022
  - Revenue: Total Revenues $240.0
  - Net income: Net Loss $(75.7)
  - EPS: Net Loss per Diluted Share $(1.52)
  - Result: reported results
  source text: to deliver results for our patients, customers, and shareholders.” FINANCIAL HIGHLIGHTS (1) ($ in millions, except per share amounts) Q3 2022 Q3 2021 % Change Total Revenues $240.0 $329.0 (27)% Net Loss $(75.7) $(32.7) * Net Loss per Diluted Share $(1.52) $(0.61) * Adjusted Net Loss (2) $(63.2) $(19.3) * Adjusted Net Loss (2) per Diluted Share $(1.27)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000141/0001367644-22-000141-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.